SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
REDUCTIONS IN ABSOLUTE IFLC AND DFLC ARE ASSOCIATED WITH PROLONGED MAJOR
ORGAN DETERIORATION PROGRESSION-FREE SURVIVAL IN PATIENTS WITH NEWLY
DIAGNOSED AL AMYLOIDOSIS RECEIVING VCD WITH OR WITHOUT DARATUMUMAB:
RESULTS FROM ANDROMEDA
Efstathios Kastritis1, Raymond L. Comenzo2, Monique C. Minnema3, Ashutosh D. Wechalekar4, Arnaud
Jaccard5, Vaishali Sanchorawala6, Hans C Lee7, Simon D. Gibbs8, Peter Mollee9, Christopher P. Venner10,
Jin Lu11, Moshe Gatt12, Kenshi Suzuki13, Kihyun Kim14, Maria Teresa Cibeira Lopez15, Meral Beksac16,
Edward Libby17, Jason Valent18, Vania T. M. Hungria19, Sandy W. Wong20, Michael Rosenzweig21, Naresh
Bumma22, Dominque Chauveau23, Meletios A. Dimopoulos24, NamPhuong Tran25, Xiang Qin26, Sandra
Y. Vasey26, Brenda Tromp27, Brendan M. Weiss26, Jessica Vermeulen27 and Giampaolo Merlini28
(1)Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of
Medicine, Athens, Greece
(2)Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical
Center, Boston
(3)Department of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, Netherlands
(4)University College London, London, United Kingdom
(5)Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoges, France
(6)Department of Medicine and Amyloidosis Center, Boston University School of Medicine and Boston
Medical Center, Boston
(7)Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD
Anderson Cancer Center, Houston
(8)The Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash University
Easter Health Clinical School, Melbourne, Australia
(9)Department of Haematology, Princess Alexandra Hospital and University of Queensland Medical
School, Brisbane, Australia
(10)Cross Cancer Institute, University of Alberta, Edmonton, Canada
(11)Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical
Research Center for Hematologic Disease, Collaborative Innovation Center of Hematology, Beijing,
China
(12)Hematology Department, Hadassah Hebrew University Medical Center, Jeruslem, Israel
(13)Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan
(14)Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,
Seoul, Korea, Republic of (South)
(15)Amyloidosis and Myeloma Unit, Hospital Clinic of Barcelona, Barcelona, Spain
(16)Department of Hematology, Ankara University, Ankara, Turkey
(17)Division of Medical Oncology, Department of Medicine, University of Washington, Seattle
(18)Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic,
Cleveland
(19)Clinica Medica São Germano, São Paulo, Brazil
(20)Department of Medicine, University of California San Francisco, San Francisco
(21)Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin
Center for Multiple Myeloma Research, City of Hope, Duarte
(22)Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus
(23)CHU de Toulouse-Hôpital Rangueil, Toulouse, France
(24)Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of
Medicine, “Alexandra” General Hospital, Athens, Greece
(25)Janssen Research & Development, LLC, Los Angeles
(26)Janssen Research & Development, LLC, Spring House, PA